3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3102-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WEIKAI C. FANG und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: DA-1726 is an oxyntomodulin analogue, acting as a dual GLP-1/glucagon receptor agonist. In this first-in-human phase 1 study (NCT06252220), a higher-dose cohort further evaluated the safety, tolerability, pharmacokinetics (PK), and preliminary pharmacodynamics of DA-1726 in obese but otherwise healthy adults.
Methods
In this 48 mg multiple-ascending dose cohort, nine patients were randomized in a 6:3 ratio to DA-1726 or placebo (PBO). Participants received once-weekly subcutaneous dosing for four weeks without titration; six entered an optional four-week extension phase at the same dose (four DA-1726; two PBO).
Results
In this interim analysis, baseline characteristics in the 48 mg DA-1726 group included mean age of 48.0±12.6 years, body weight 110.4±12.7 kg, and BMI 38.1±3.3 kg/m². During four-weeks of treatment, gastrointestinal (GI) adverse events (AEs) were mainly transient and mild-to-moderate, with no treatment-related discontinuations or serious AEs. PK through Day 50 supported once-weekly dosing with sustained exposure (Cmax 1,397.1±245.0 nM; AUCinf 193,728±29,834 h*nM), terminal half-life of 103.8±20.0 hours, and accumulation ratio of 1.44. Dose-proportional PK with sustained exposure supported weight and anthropometric reductions. In the 48 mg cohort, mean body weight reductions from baseline were 6.1% at Day 26 and 9.1% at Day 54 (p<0.05 vs PBO at Day 26), continuing through Week 8 without evidence of plateau. Significant reductions were also observed in waist circumference (−5.8 cm at Day 22; −9.8 cm at Day 54; p<0.05 vs PBO) and BMI (−2.3 kg/m² at Day 26; −3.4 kg/m² at Day 54; p<0.05 vs PBO at Day 26).
Conclusion
DA-1726 was generally well tolerated up to 48 mg, with mainly mild-to-moderate GI AEs and no new safety signals. Clinically meaningful, statistically significant body weight reductions at higher doses were consistent with the dose-proportional PK profile and support continued development for obesity. Disclosure W.C. Fang: Consultant; Current; MetaVia Therapeutics. Y. Chae: None. D. Lee: None. E. Kim: None. R. Homolka: Employee; Ended; MetaVia Inc. J. Lee: Employee; Current; MetaVia Inc. K. Lee: Employee; Current; MetaVia Inc., Dong-A ST Co., Ltd. S. Kim: Employee; Current; MetaVia Inc., Dong-A ST Co., Ltd. M. Kim: None. H. Kim: None.
Zitieren
APA
FANG, W. C., CHAE, Y., LEE, D. Y., KIM, E., HOMOLKA, R., LEE, J. E., LEE, K., KIM, S., KIM, M., & KIM, H. H. (2026). 3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3102-lb
Vancouver
FANG WC, CHAE Y, LEE DY, KIM E, HOMOLKA R, LEE JE, et al. 3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3102-lb
BibTeX
@article{FANG2026,
author = {FANG, WEIKAI C. and CHAE, YUNA and LEE, DAE YOUNG and KIM, EUNJIN and HOMOLKA, ROBERT and LEE, JI EUN and LEE, KYUNGHYUN and KIM, SUNGJIN and KIM, MI-KYUNG and KIM, HYUNG HEON},
title = {3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3102-lb}
}
EUVIMED